Tiziana Life Sciences plc Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes; Findings may h

Tiziana Life Sciences plc

Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays

in progression of Type 1 Diabetes; Findings may have the potential to expand therapeutic benefits of Tiziana's Foralumab,

the only known fully human anti-CD3 mAb

party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression

of Type 1 diabetes in high risk population

Life Sciences plc (Nasdaq: TLSA/ AIM: TILS ("Tiziana" or the "Company"), a biotechnology company focusing

on the discovery and development of innovative therapeutics for inflammation and oncology indications, notes that a recently published

study in The New England Journal of Medicine titled, "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for

Type 1 Diabetes," provides clinical evidence for the potential use of an anti-CD3 mAb in the prevention or treatment

of Type 1 diabetes. Teplizumab is being developed by Provention Bio. The published study was funded by the National Institute of

Health and others, and was conducted by investigators at numerous institutions in the field of immunology and pediatrics including

Yale University and Vanderbuilt University.

published results from a Phase 2 trial of Teplizumab, a mouse derived anti-CD3 mAb delivered intravenously, evaluated 76 patients

who had relatives with Type 1 diabetes. 72% of subjects were under the age of 18. Patients were randomized and treated with either

a 14-day course of Teplizumab or placebo. At 6 month intervals, the study tested subjects for the onset of Type 1 diabetes. Teplizumab

was found to significantly slow progression to clinical Type 1 diabetes, with a median delay in the diagnosis of diabetes of 2

years. At the end of the trial, 57% of the group treated with Teplizumab were diabetes free, while 28% of the group treated with

placebo remained diabetes free.

and adults at high risk of developing Type 1 diabetes may benefit from safe and effective prophylactic use of anti-CD3 mAb's.

We congratulate Prof. Kevan Herold, a member of Tiziana's Scientific Advisory Board, and the research team that conducted

the published study. Tiziana's proprietary technology for the oral and nasal delivery of mAb's in general, and Foralumab

specifically, have strong potential indications in autoimmune diseases including Type 1 diabetes," stated Kunwar Shailubhai,

CEO & CSO of Tiziana.

Foralumab offers potential safety and efficacy advantages over other anti-CD3 mAb's because it is the only fully human anti-CD3

mAb, as compared to mouse derived anti-CD3s which have been shown to cause immune reactions in humans. Tiziana's proprietary

platform technology for oral and nasal administration of mAb's could provide clinical benefits by mimicking the body's

natural immune modulation processes and thereby increasing patient compliance.

is currently in a Phase 1 trial at the Harvard Medical School in healthy volunteers to study safety, tolerability and biomarkers

of neurodegenerative disease through nasal delivery. An upcoming Phase 1 trial will evaluate oral Foralumab's safety, tolerability

and biomarkers in Crohn's disease and NASH. A Phase 2 trial in Crohn's and NASH is expected to commence next year.

(hOKT3 1 (Ala-Ala) is a humanized version of the mouse monoclonal antibody, OKT3, which retains the same binding regions

of OKT3. Being humanized, the antibody appears to have a decreased cytokine release potential since its Fc region has been changed

(mutated) to not bind to the FcR on T cells but successfully maintains its immunomodulatory properties. Teplizumab is being evaluated

in autoimmune diseases such as Type I diabetes and clinical trials have shown promise in lowering HbA1c levels and lower insulin

requirements in new onset Type I diabetes patients as well as slowing progression of Type I diabetes in high risk patients.

(formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients

with Crohn's disease with decreases in the classic side effects of cytokine release syndrome (CRS) and improves the overall safety

profile of Foralumab. In a humanized mouse model , it was shown that while targeting the T cell receptor, orally administered Foralumab

modulates immune responses of the T cells, enhances Tregs and thus provides therapeutic benefit in treating inflammatory and autoimmune

diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. Based on animal studies,

the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases

in a safe manner by the induction of Tregs.

Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat

human disease in oncology and immunology. The Company is also developing Foralumab for liver diseases. Foralumab is the only fully

human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide

range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS),

ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis,

where modulation of a T-cell response is desirable.

Receive news and updates from Tiziana Life Sciences plc by signing

up to get email alerts straight to you email on https://ir.tizianalifesciences.com/

For further enquiries: